BCL2 and neuroblastoma: Our analysis revealed that neuroblastoma zccs373 was most differentially sensitive to aurora-A kinase (AURKA) inhibitor alisertib and B-cell leukaemia/lymphoma 2 (BCL-2) inhibitor venetoclax (Fig. 6D).